C-type lectin domain family 1 member B (also termed CLEC-1b, C-type lectin-like receptor 2, CLEC-2, CLEC2, CLEC2B, PRO1384, QDED721, C-type lectin domain family 1 member B, CLEC1B, activation-induced C-type lectin, AICL, and 1810061I13Rik) is a cell surface receptor protein. It binds certain biomolecules that act as ligands that when bound to the CLEC-1b expressed by cells stimulates certain functions in these cells. The human CLEC-1b receptor is encoded by the CLEC1Bgene which is located on the short (i.e., "p")-arm of chromosome 12 at region 1, band 3, sub-band 1 to sub-band 2 (position notated as 12p13.31-p13.2).<https://www.ncbi.nlm.nih.gov/gene/387836> Most of the recent literature terms the C-type lectin domain family 1 member B as CLEC-2. Since current reports commonly use CLEC-2 rather than CLEC-1b, CLEC-2 will be used here in place of CLEC1b in further describing this protein.
CLEC-2 is a member of the broad family of pattern recognition receptors (i.e., PRRs). Vertebrate PRRs can be classified into five types based on their structural similarities: a) toll-like receptors, b) NOD-like receptors, c) RIG-I-like receptors, d) AIM2 (also termed absent in melanoma 2 or interferon-inducible protein AIM2), and e) C-type lectin receptors (i.e., CLR). CLRs are a superfamily of more than 1,000 proteins. They are subdivided into 17 subgroups. All members of this family possess one or more C-type lectin-like domains, i.e., protein domains that have a characteristic loop-in-a-loop structure formed by their amino acid sequences which form a large loop that encloses a smaller, internal loop or some other type of secondary structure. These internal loops or other structures are formed by two disulfide bridges located at the bases of these loops. CLEC-2 is a C-type lectin receptor.
Studies in isolated human and mouse aortas and mice strongly suggest that the S100A13 expressed on the surface of smooth muscle cells is responsible for activating platelets and causing thrombus formation during the early stages of thrombus formation before podoplanin is expressed.
C-type lectin domain family 7 member A activation of CLEC-2
Studies in various cultured cell systems indicate that the CLEC7A (i.e., C-type lectin domain family 7 member protein, also termed dectin-1) from humans (sometimes notated as hdectin-1) as well as the dectin-1 proteins isolated from the cells of higher primates activate human as well as mouse CLEC-2. However, the CLEC7A protein isolated from mouse cells (sometimes notated as mdectin-1) does not activate human or mouse CLEC-2. A structurally similar protein, CLEC6A (i.e., C-type lectin domain containing 6A, also termed dectin-2) has a very different set of actions and does not activate CLEC-2. CLEC7A (i.e., dectin-1) in humans is expressed on the surface membranes of vascular endothelial cells, tissue dendritic cells, tissue macrophages, and circulating white blood cells such as neutrophils, monocytes, and circulating dendritic cells. CLEC7A identifies and interacts with various fungi (e.g., yeast, Candida albicans, Pneumocystis jirovecii and Aspergillus species to promote immune responses against these pathogens. CLEC7A also stimulates isolated human platelets and mouse platelets made to express human CLEC-2 but not mouse platelets expressing mouse CLEC-2. Further studies in mice made to express human CLEC-2 in place of mouse CLEC2 were found to stimulate platelets without triggering venous thromboses whereas podoplanin triggered both platelet activation and venous thromboses. These latter findings suggest that CLEC7A is a comparatively moderate antihemorrhagic agent (i.e., inhibitor of bleeding) which may control physiological processes through platelets thrombosis-independent mechanisms. Further studies may show that CLEC-2 is useful for inhibiting bleeding without causing thrombosis.